Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

Group B streptococcus is the leading cause of infection in newborns

Group B streptococcus is the leading cause of infection in newborns

The findings suggest that this disturbing trend could be due the emergence of more virulent group B streptococcal strains and call for a renewed evaluation of preventive strategies to reduce neonatal disease. [More]
New specialist outpatient vaccinations clinic for at-risk people to be opened at MedUni Vienna

New specialist outpatient vaccinations clinic for at-risk people to be opened at MedUni Vienna

At the Medical University of Vienna, Austria's first specialist vaccinations clinic for at-risk groups will open on 22nd October 2014 with an "Open Doors Day". This clinic specialises in patients who, as a result of illness or disease, require personalised care in relation to vaccinations. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive. [More]
UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

The UCSF Clinician Consultation Center at San Francisco General Hospital and Trauma Center has been funded by the Centers for Disease Control and Prevention to provide a PrEPline, a telephone consultation service that gives expert guidance to healthcare providers across the nation who prescribe antiretroviral medications to HIV uninfected individuals to prevent HIV. [More]
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]
New NIH program awards $2.5 million to spur innovation in mobile health

New NIH program awards $2.5 million to spur innovation in mobile health

A new NIH program is awarding nearly $2.5 million to spur innovation in mobile communication technologies and software applications used in biomedical research in low- and middle-income countries (LMICs). [More]
New evidence-based guidelines for prevention, treatment of POAF

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures. [More]
Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). [More]
Expert creates new evidence-based guideline for managing sickle cell disease

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA. [More]
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm. [More]
Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. [More]
First Edition: August 12, 2014

First Edition: August 12, 2014

Today's headlines include stories about how the federal government's experience with healthcare.gov has led to the creation of the U.S. Digital Service. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]
Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union. [More]
Continuous antibiotics for children with antenatal hydronephrosis not necessary, study finds

Continuous antibiotics for children with antenatal hydronephrosis not necessary, study finds

Up to 5 percent of all prenatal ultrasounds uncover antenatal hydronephrosis, or enlarged kidneys, the most commonly detected prenatal abnormality in the United States. Many children with this abnormality are treated continually with preventive antibiotics for the first few years of life with the hopes of preventing the condition's associated urinary tract infections. [More]
Lancet report: Support sex workers to prevent HIV

Lancet report: Support sex workers to prevent HIV

Across the world, in high- and low-income countries, women, men, and transgender people who sell sex are subjected to repressive and discriminatory law, policy, and practice, which in turn fuel human rights violations against them, including violence and discrimination. All of these factors are preventing sex workers from accessing the services which they need in order to effectively prevent and treat HIV infection, according to a major new Series on HIV and sex workers, published in The Lancet. [More]
New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation. [More]